Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

February 8, 2013

7.5mg Tablets Additionally Approved - Samsca^®, Vasopressin V2 Receptor Antagonist

Tokyo, Japan, February 8, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca^® (tolvaptan), vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, was granted additional approval of tablets in 7.5mg dosage on February 4, 2013.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

7.5mg Tablets Additionally Approved - Samsca^®, Vasopressin V2 Receptor Antagonist

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan